Navigation Links
A Settlement Over Stem Cell Controversy Through Scientific Research

The successful attempts of scientists to create stem cells that resemble those of the embryonic origin, in addition to reprogramming to the embryonic state could eliminate the need for creation and destruction of human embryos for the same. //

If future experiments are directed to ensure that this reprogrammed state would be maintained even after removal of the embryonic stem cell DNA, currently a technical hurdle, the hybrid cells could theoretically be used to produce embryonic stem cells lines that are tailored to individual patients without the need to exploit human embryos.

The hybrid cells created by the team had the appearance, growth rate, and several key genetic characteristics of human embryonic cells. They also behaved like embryonic cells, differentiating into cells from each of the three main tissue types that form in a developing embryo.

This would not only save the embryos from being used for scientific purposes but also eliminate the controversy that exists over stem cell research at the present, circumventing some of the logistical and societal concerns. The above study has used laboratory grown human embryonic stem cells that have already been approved for use by federally funded researchers.

Not much is known about the feasibility of the procedure presently, but has led to an understanding that human embryonic cells have the ability to reprogram adult cell chromosomes following cell fusion.
'"/>




Page: 1

Related medicine news :

1. Is Workers’ Comp. Settlements for Back Pain Fair
2. Solutions Possible for Providing Water and Sanitation in Poor Urban Settlements, Says WaterAid
3. Herbal Drug In Controversy
4. The Existing Controversy of Hormone Replacement Therapy
5. Controversy over spread of Mad Cow disease from India
6. French Fries In Cancer Controversy In China
7. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
8. Controversy: Malaria Vaccine - Future Possibility Or Just A Dream?
9. The Looming Controversy Surrounding Facial Transplant
10. Controversy over Healthy diet may lead to less red meat in diet
11. Controversy over Copeman Healthcare fee
Post Your Comments:
(Date:12/2/2008)...tCall/ -- Quest Diagnostics Incorporated (NYSE: ...testing, information and services, announced that ...thcare Conference in New York City today, December...cheduled to begin at 4:00 p.m. Eastern Time. , ...affirm its 2008 guidance for revenue growth of gre...
(Date:12/2/2008)...er with aprotinin, a drug commonly used to control...y, compared with lysine analogues, according to a ...9 to be published in the January 20th issue of C...dvisory panel will meet to decide on aprotinin use...the meeting. , The study, a systematic review o...
(Date:12/2/2008)...rstCall/ - NUCRYST Pharmaceuticals Corp., a develo...t infection and inflammation, announced today that...rity shareholder, The Westaim Corporation ("Westai...areholders to consider a return of capital of US$0...s to a return of capital of approximately US$15 mi...
(Date:12/2/2008)...e Efficacy of Commercially Available Hypomethylati... Eisai Corporation of North Americ...rst clinical trial evaluating the activity of Daco...za(R) (azacitidine) in adult patients with interme...ic syndromes (MDS), a potentially life-threatening...
Breaking Medicine News(10 mins):Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3
... of Public Health have reported that over the coun...eneficial as they can lower the risk of Parkinson’... took daily one ibuprofen tablet, men and women, f...eople seemed to have a 38% less chance of having P...
... increased calcium intake by drinking milk or othe...of Parkinson’s disease. Parkinson’s disease is a d...s are muscle tremors, muscle rigidity, decreased m...low voluntary movements, and a mask-like facial ex...
... out how to elevate the functional limitations of ...e researchers of Feinberg School of Medicine, US ...and old with arthritis. Functions, which were chec...ng to daily living and specialized activities of d...
...ncy is associated with dental problems. But are th...trong enough to affect the babies’ birth weight or...ew York University College of Dentistry, US, say t...a affect the pregnancy by causing pre-term deliver...
Other Medicine News:
(Date:11/25/2008)...ss Survival of Patients Receiving Litx versus Stan...ular Carcinoma , , BELLEVUE, Wash., Nov. 25...O) today announced the completion of enrollment in... Therapy(TM) (Litx(TM)) as a treatment for unresec...s hepatoma or primary liver cancer. , , The...
(Date:11/24/2008)...ewswire/ -- Takeda Pharmaceutical Company Limited ...earch & Development Center, Inc., U.S., announ... the U.S. Food and Drug Administration (FDA) recom...eatment of hyperuricemia in patients with gout. Th...ne panel member abstaining. The vote followed pres...
(Date:11/24/2008).../ -- Leaders of Schering-Plough Corporation (NYSE:... the company,s research pipeline, highlighting a r...entities in clinical trials or under regulatory re...search and development is adding strength and brea...mation," said Fred Hassan, chairman and CEO. "Our...
(Date:11/24/2008)... long-term commitment to hepatitis research , ...ll/ -- Schering-Plough Corporation (NYSE: SGP ) ...s lead investigational oral hepatitis C protease i...company believes boceprevir has the potential to b...bitor for treating chronic hepatitis C. The compa...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 1Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 2Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 3Using DNA scientists hunt for the roots of the modern potato 2050 1Using DNA scientists hunt for the roots of the modern potato 2050 2American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 1American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 2Flextronics Announces Third Quarter Results 10427 1Flextronics Announces Third Quarter Results 10427 2Flextronics Announces Third Quarter Results 10427 3Flextronics Announces Third Quarter Results 10427 4Flextronics Announces Third Quarter Results 10427 5Flextronics Announces Third Quarter Results 10427 6Flextronics Announces Third Quarter Results 10427 7Flextronics Announces Third Quarter Results 10427 8Flextronics Announces Third Quarter Results 10427 9Flextronics Announces Third Quarter Results 10427 10Flextronics Announces Third Quarter Results 10427 11Flextronics Announces Third Quarter Results 10427 12Flextronics Announces Third Quarter Results 10427 13Flextronics Announces Third Quarter Results 10427 14Flextronics Announces Third Quarter Results 10427 15Flextronics Announces Third Quarter Results 10427 16Flextronics Announces Third Quarter Results 10427 17Flextronics Announces Third Quarter Results 10427 18Flextronics Announces Third Quarter Results 10427 19
...Calif., June 05, 2007 /PRNewswire/ -- MAP,Pharmace... Phase 2,data from its MAP0004 migraine therapy cl...e Society Meeting at the Hyatt Regency,Chicago in ...was,accepted as a late-breaker, is entitled Rapid ...led Dihydroergotamine Mesylate,via a Novel Inhaler...
...une 05, 2007 /PRNewswire/ -- , Professor Home said...ppointing and,misleading in that they disregarded ...nt to patients and physicians. Most,significantly ...e,of any increase in cardiovascular death or death...T: Professor Philip Home, (44) 778-525-1736 , Ter...
Other Medicine Technology:MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting 2
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...
Medicine Products: